Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 379.33 million. The enterprise value is 385.77 million.
| Market Cap | 379.33M |
| Enterprise Value | 385.77M |
Important Dates
The last earnings date was Monday, September 8, 2025.
| Earnings Date | Sep 8, 2025 |
| Ex-Dividend Date | May 5, 2025 |
Share Statistics
Pharmanutra has 9.60 million shares outstanding. The number of shares has decreased by -0.31% in one year.
| Current Share Class | 9.60M |
| Shares Outstanding | 9.60M |
| Shares Change (YoY) | -0.31% |
| Shares Change (QoQ) | -3.62% |
| Owned by Insiders (%) | 10.77% |
| Owned by Institutions (%) | 12.54% |
| Float | 4.25M |
Valuation Ratios
The trailing PE ratio is 22.46 and the forward PE ratio is 17.75.
| PE Ratio | 22.46 |
| Forward PE | 17.75 |
| PS Ratio | 3.10 |
| PB Ratio | 6.19 |
| P/TBV Ratio | 10.16 |
| P/FCF Ratio | 48.02 |
| P/OCF Ratio | 30.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.46, with an EV/FCF ratio of 48.84.
| EV / Earnings | 22.83 |
| EV / Sales | 3.16 |
| EV / EBITDA | 12.46 |
| EV / EBIT | 14.13 |
| EV / FCF | 48.84 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.36.
| Current Ratio | 2.06 |
| Quick Ratio | 1.75 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | 0.71 |
| Debt / FCF | 2.80 |
| Interest Coverage | 31.48 |
Financial Efficiency
Return on equity (ROE) is 28.96% and return on invested capital (ROIC) is 20.65%.
| Return on Equity (ROE) | 28.96% |
| Return on Assets (ROA) | 15.00% |
| Return on Invested Capital (ROIC) | 20.65% |
| Return on Capital Employed (ROCE) | 32.25% |
| Revenue Per Employee | 1.04M |
| Profits Per Employee | 143,195 |
| Employee Count | 118 |
| Asset Turnover | 1.07 |
| Inventory Turnover | 6.66 |
Taxes
In the past 12 months, Pharmanutra has paid 10.53 million in taxes.
| Income Tax | 10.53M |
| Effective Tax Rate | 38.51% |
Stock Price Statistics
The stock price has decreased by -32.36% in the last 52 weeks. The beta is 0.32, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -32.36% |
| 50-Day Moving Average | 45.55 |
| 200-Day Moving Average | 49.79 |
| Relative Strength Index (RSI) | 19.84 |
| Average Volume (20 Days) | 18,659 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 122.25 million and earned 16.90 million in profits. Earnings per share was 1.76.
| Revenue | 122.25M |
| Gross Profit | 64.49M |
| Operating Income | 27.30M |
| Pretax Income | 27.34M |
| Net Income | 16.90M |
| EBITDA | 30.49M |
| EBIT | 27.30M |
| Earnings Per Share (EPS) | 1.76 |
Balance Sheet
The company has 15.68 million in cash and 22.13 million in debt, giving a net cash position of -6.45 million or -0.67 per share.
| Cash & Cash Equivalents | 15.68M |
| Total Debt | 22.13M |
| Net Cash | -6.45M |
| Net Cash Per Share | -0.67 |
| Equity (Book Value) | 61.25M |
| Book Value Per Share | 6.52 |
| Working Capital | 33.01M |
Cash Flow
In the last 12 months, operating cash flow was 12.31 million and capital expenditures -4.41 million, giving a free cash flow of 7.90 million.
| Operating Cash Flow | 12.31M |
| Capital Expenditures | -4.41M |
| Free Cash Flow | 7.90M |
| FCF Per Share | 0.82 |
Margins
Gross margin is 52.75%, with operating and profit margins of 22.33% and 13.82%.
| Gross Margin | 52.75% |
| Operating Margin | 22.33% |
| Pretax Margin | 22.36% |
| Profit Margin | 13.82% |
| EBITDA Margin | 24.94% |
| EBIT Margin | 22.33% |
| FCF Margin | 6.46% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.53%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 2.53% |
| Dividend Growth (YoY) | 17.65% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 56.87% |
| Buyback Yield | 0.31% |
| Shareholder Yield | 2.84% |
| Earnings Yield | 4.45% |
| FCF Yield | 2.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |